{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:39:15Z","timestamp":1790854755985,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Womens Ment Health"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Antipsychotic-induced prolactin elevation may impede protective effects of estrogens in women with schizophrenia-spectrum disorders (SSD). Our study sought to confirm whether the use of prolactin-raising antipsychotics is associated with lower estrogen levels, and to investigate how estrogen and prolactin levels relate to symptom severity and cognition in premenopausal women with SSD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This cross-sectional study included 79 premenopausal women, divided in three groups of women with SSD treated with prolactin-sparing antipsychotics (\n                      <jats:italic>n\u2009=<\/jats:italic>\n                      \u200921) or prolactin-raising antipsychotics (\n                      <jats:italic>n\u2009=<\/jats:italic>\n                      \u200927), and age-matched women without SSD (\n                      <jats:italic>n\u2009=<\/jats:italic>\n                      \u200931). Circulating 17\u03b2-estradiol was compared among groups. In patients, we assessed the relationship between prolactin and 17\u03b2-estradiol, and the relationships of these hormones to symptom severity and cognition, using correlation analyses and backward regression models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In women receiving prolactin-raising antipsychotics, 17\u03b2-estradiol levels were lower as compared to both other groups (\n                      <jats:italic>H(<\/jats:italic>\n                      2)\u2009=\u20098.34;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.015), and prolactin was inversely correlated with 17\u03b2-estradiol (\n                      <jats:italic>r<\/jats:italic>\n                      =-0.42,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.030). In the prolactin-raising group, 17\u03b2-estradiol correlated positively with verbal fluency (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.52,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009), and 17\u03b2-estradiol and prolactin together explained 29% of the variation in processing speed (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      <jats:sub>17\u03b2\u2212estradiol<\/jats:sub>\n                      \u2009=\u20090.24,\n                      <jats:italic>\u03b2<\/jats:italic>\n                      <jats:sub>prolactin\u00a0<\/jats:sub>\n                      =\u00a0-0.45,\n                      <jats:italic>F<\/jats:italic>\n                      (2,25)\u2009=\u20095.98,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008). In the prolactin-sparing group, 17\u03b2-estradiol correlated negatively with depression\/anxiety (\n                      <jats:italic>r\u00a0<\/jats:italic>\n                      =\u00a0-0.57,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014), and together with prolactin explained 26% of the variation in total symptoms (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      <jats:sub>17\u03b2\u2212estradiol<\/jats:sub>\n                      \u00a0=\u00a0-0.41,\n                      <jats:italic>\u03b2<\/jats:italic>\n                      <jats:sub>prolactin<\/jats:sub>\n                      \u2009=\u20090.32,\n                      <jats:italic>F<\/jats:italic>\n                      (2,18)\u2009=\u20094.44,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In women with SSD, antipsychotic-induced prolactin elevation was related to lower estrogen levels. Further, estrogens negatively correlated with symptom severity and positively with cognition, whereas prolactin levels correlated negatively with cognition. Our findings stress the clinical importance of maintaining healthy levels of prolactin and estrogens in women with SSD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00737-024-01491-9","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T03:02:07Z","timestamp":1720753327000},"page":"931-941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Antipsychotic-induced prolactin elevation in premenopausal women with schizophrenia: associations with estrogen, disease severity and cognition"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2383-0851","authenticated-orcid":false,"given":"Bodyl A.","family":"Brand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna N.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elske J. M.","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia S.","family":"Weickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris E.","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Weickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"1491_CR1","doi-asserted-by":"publisher","unstructured":"Barth C, Villringer A, Sacher J (2015) Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Front Neurosci 9. https:\/\/doi.org\/10.3389\/fnins.2015.00037","DOI":"10.3389\/fnins.2015.00037"},{"key":"1491_CR2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.schres.2004.06.013","volume":"73","author":"N Bergemann","year":"2005","unstructured":"Bergemann N, Mundt C, Parzer P et al (2005) Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res 73:357\u2013366. https:\/\/doi.org\/10.1016\/j.schres.2004.06.013","journal-title":"Schizophr Res"},{"key":"1491_CR3","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1017\/S0033291707000578","volume":"37","author":"N Bergemann","year":"2007","unstructured":"Bergemann N, Parzer P, Runnebaum B et al (2007) Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol Med 37:1427\u20131436. https:\/\/doi.org\/10.1017\/S0033291707000578","journal-title":"Psychol Med"},{"key":"1491_CR5","doi-asserted-by":"publisher","first-page":"100681","DOI":"10.1016\/j.conctc.2020.100681","volume":"20","author":"BA Brand","year":"2020","unstructured":"Brand BA, de Boer JN, Oude Ophuis SBJ et al (2020) Raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a study protocol. Contemp Clin Trials Commun 20:100681. https:\/\/doi.org\/10.1016\/j.conctc.2020.100681","journal-title":"Contemp Clin Trials Commun"},{"key":"1491_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/YCO.0000000000000699","volume":"34","author":"BA Brand","year":"2021","unstructured":"Brand BA, de Boer JN, Sommer IEC (2021) Estrogens in schizophrenia: progress, current challenges and opportunities. Curr Opin Psychiatry 34:228\u2013237. https:\/\/doi.org\/10.1097\/YCO.0000000000000699","journal-title":"Curr Opin Psychiatry"},{"key":"1491_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1017\/S0033291721004591","volume":"52","author":"BA Brand","year":"2022","unstructured":"Brand BA, Haveman YRA, de Beer F et al (2022) Antipsychotic medication for women with schizophrenia spectrum disorders. Psychol Med 52:649\u2013663. https:\/\/doi.org\/10.1017\/S0033291721004591","journal-title":"Psychol Med"},{"key":"1491_CR4","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1093\/schbul\/sbad058","volume":"49","author":"BA Brand","year":"2023","unstructured":"Brand BA, de Boer JN, Marcelis MC et al (2023) The Direct and Long-Term effects of Raloxifene as Adjunctive Treatment for Schizophrenia-Spectrum disorders: a Double-Blind, randomized clinical trial. Schizophr Bull 49:1579\u20131590. https:\/\/doi.org\/10.1093\/schbul\/sbad058","journal-title":"Schizophr Bull"},{"key":"1491_CR8","unstructured":"Bratek A, Ko\u017amin-Burzy\u0144ska A, Krysta K et al (2015) Effects of hormones on cognition in schizophrenic male patients\u2013preliminary results. Psychiatr Danub"},{"key":"1491_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/0269881107088435","volume":"22","author":"C Bushe","year":"2008","unstructured":"Bushe C, Shaw M, Peveler RC (2008) A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 22:46\u201355. https:\/\/doi.org\/10.1177\/0269881107088435","journal-title":"J Psychopharmacol"},{"key":"1491_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0165-1781(02)00123-3","volume":"111","author":"CM Canuso","year":"2002","unstructured":"Canuso CM, Goldstein JM, Wojcik J et al (2002) Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res 111:11\u201320. https:\/\/doi.org\/10.1016\/S0165-1781(02)00123-3","journal-title":"Psychiatry Res"},{"key":"1491_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.schres.2011.05.018","volume":"131","author":"L Citrome","year":"2011","unstructured":"Citrome L, Meng X, Hochfeld M (2011) Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Res 131:75\u201381. https:\/\/doi.org\/10.1016\/j.schres.2011.05.018","journal-title":"Schizophr Res"},{"key":"1491_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ajp.2015.07.016","volume":"18","author":"TL da Silva","year":"2015","unstructured":"da Silva TL, Ravindran AV (2015) Contribution of sex hormones to gender differences in schizophrenia: a review. Asian J Psychiatr 18:2\u201314. https:\/\/doi.org\/10.1016\/j.ajp.2015.07.016","journal-title":"Asian J Psychiatr"},{"key":"1491_CR74","unstructured":"Department of Psychiatry University of Oxford"},{"key":"1491_CR13","doi-asserted-by":"publisher","unstructured":"Ferrara M, Srihari VH (2020) Early Intervention for Psychosis in the United States: Tailoring Services to Improve Care for Women. https:\/\/doi.org\/101176\/appi.ps202000205 72:5\u20136. https:\/\/doi.org\/10.1176\/APPI.PS.202000205","DOI":"10.1176\/APPI.PS.202000205"},{"key":"1491_CR14","unstructured":"First MB (2007) Structured clinical interview for DSM-IV-TR axis I disorders: SCID-I: biometrics research department"},{"key":"1491_CR15","doi-asserted-by":"publisher","first-page":"109941","DOI":"10.1016\/j.pnpbp.2020.109941","volume":"101","author":"A Gonz\u00e1lez-Rodr\u00edguez","year":"2020","unstructured":"Gonz\u00e1lez-Rodr\u00edguez A, Labad J, Seeman MV (2020) Antipsychotic-induced hyperprolactinemia in aging populations: prevalence, implications, prevention and management. Prog Neuropsychopharmacol Biol Psychiatry 101:109941. https:\/\/doi.org\/10.1016\/j.pnpbp.2020.109941","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1491_CR16","doi-asserted-by":"crossref","unstructured":"Grigg J, Worsley R, Thew C et al (2017) Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl","DOI":"10.1007\/s00213-017-4730-6"},{"key":"1491_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.psyneuen.2018.06.022","volume":"96","author":"C Gurvich","year":"2018","unstructured":"Gurvich C, Gavrilidis E, Worsley R et al (2018) Menstrual cycle irregularity and menopause status influence cognition in women with schizophrenia. Psychoneuroendocrinology 96:173\u2013178. https:\/\/doi.org\/10.1016\/j.psyneuen.2018.06.022","journal-title":"Psychoneuroendocrinology"},{"key":"1491_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/026988110401800307","author":"R Halari","year":"2004","unstructured":"Halari R, Kumari V, Mehrotra R et al (2004) The relationship of sex hormones and cortisol with cognitive functioning in schizophrenia. J Psychopharmacol. https:\/\/doi.org\/10.1177\/026988110401800307","journal-title":"J Psychopharmacol"},{"key":"1491_CR19","doi-asserted-by":"crossref","unstructured":"Hampson E (2020) A brief guide to the menstrual cycle and oral contraceptive use for researchers in behavioral endocrinology. Horm Behav","DOI":"10.1016\/j.yhbeh.2019.104655"},{"key":"1491_CR20","doi-asserted-by":"publisher","first-page":"105218","DOI":"10.1016\/j.psyneuen.2021.105218","volume":"128","author":"K Hazelgrove","year":"2021","unstructured":"Hazelgrove K, Biaggi A, Waites F et al (2021) Risk factors for postpartum relapse in women at risk of postpartum psychosis: the role of psychosocial stress and the biological stress system. Psychoneuroendocrinology 128:105218. https:\/\/doi.org\/10.1016\/j.psyneuen.2021.105218","journal-title":"Psychoneuroendocrinology"},{"key":"1491_CR21","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/IJNP\/PYAC023","volume":"25","author":"M Hidalgo-Figueroa","year":"2022","unstructured":"Hidalgo-Figueroa M, Salazar A, Romero-L\u00f3pez-Alberca C et al (2022) The influence of Oxytocin and Prolactin during a first episode of psychosis: the implication of sex differences, clinical features, and cognitive performance. Int J Neuropsychopharmacol 25:666\u2013677. https:\/\/doi.org\/10.1093\/IJNP\/PYAC023","journal-title":"Int J Neuropsychopharmacol"},{"key":"1491_CR22","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.158.7.1134","volume":"158","author":"AL Hoff","year":"2001","unstructured":"Hoff AL, Kremen WS, Wieneke MH et al (2001) Association of Estrogen Levels with Neuropsychological Performance in Women with Schizophrenia. Am J Psychiatry 158:1134\u20131139. https:\/\/doi.org\/10.1176\/appi.ajp.158.7.1134","journal-title":"Am J Psychiatry"},{"key":"1491_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/J.BPOBGYN.2021.10.009","volume":"81","author":"E Hogervorst","year":"2022","unstructured":"Hogervorst E, Craig J, O\u2019Donnell E (2022) Cognition and mental health in menopause: a review. Best Pract Res Clin Obstet Gynaecol 81:69\u201384. https:\/\/doi.org\/10.1016\/J.BPOBGYN.2021.10.009","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"1491_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0306-4530(00)00034-2","volume":"26","author":"TJ Huber","year":"2001","unstructured":"Huber TJ, Rollnik J, Wilhelms J et al (2001) Estradiol levels in psychotic disorders. Psychoneuroendocrinology 26:27\u201335. https:\/\/doi.org\/10.1016\/S0306-4530(00)00034-2","journal-title":"Psychoneuroendocrinology"},{"key":"1491_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.euroneuro.2013.11.012","volume":"24","author":"E Huerta-Ramos","year":"2014","unstructured":"Huerta-Ramos E, Iniesta R, Ochoa S et al (2014) Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol 24:223\u2013231","journal-title":"Eur Neuropsychopharmacol"},{"key":"1491_CR26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00406-019-01079-w","volume":"270","author":"E Huerta-Ramos","year":"2020","unstructured":"Huerta-Ramos E, Labad J, Cobo J et al (2020) Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial. Eur Arch Psychiatry Clin Neurosci 270:729\u2013737. https:\/\/doi.org\/10.1007\/s00406-019-01079-w","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1491_CR27","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J et al (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394:939\u2013951. https:\/\/doi.org\/10.1016\/S0140-6736(19)31135-3","journal-title":"Lancet"},{"key":"1491_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/FTD.0000000000000585","volume":"41","author":"AK J\u00f6nsson","year":"2019","unstructured":"J\u00f6nsson AK, Spigset O, Reis M (2019) A compilation of serum concentrations of 12 antipsychotic drugs in a therapeutic drug monitoring setting. Ther Drug Monit 41:348\u2013356. https:\/\/doi.org\/10.1097\/FTD.0000000000000585","journal-title":"Ther Drug Monit"},{"key":"1491_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261\u2013276. https:\/\/doi.org\/10.1093\/schbul\/13.2.261","journal-title":"Schizophr Bull"},{"key":"1491_CR76","doi-asserted-by":"publisher","unstructured":"Keefe R (2004) The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 68:283\u2013297. https:\/\/doi.org\/10.1016\/j.schres.2003.09.011","DOI":"10.1016\/j.schres.2003.09.011"},{"key":"1491_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000093780","volume":"53","author":"Y-H Ko","year":"2006","unstructured":"Ko Y-H, Joe S-H, Cho W et al (2006) Estrogen, cognitive function and negative symptoms in female Schizophrenia. Neuropsychobiology 53:169\u2013175. https:\/\/doi.org\/10.1159\/000093780","journal-title":"Neuropsychobiology"},{"key":"1491_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2014.33","author":"J Kulkarni","year":"2015","unstructured":"Kulkarni J, Gavrilidis E, Wang W et al (2015) Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry. https:\/\/doi.org\/10.1038\/mp.2014.33","journal-title":"Mol Psychiatry"},{"key":"1491_CR31","doi-asserted-by":"publisher","first-page":"100743","DOI":"10.1016\/j.yfrne.2019.03.002","volume":"53","author":"J Kulkarni","year":"2019","unstructured":"Kulkarni J, Butler S, Riecher-R\u00f6ssler A (2019) Estrogens and SERMS as adjunctive treatments for schizophrenia. Front Neuroendocrinol 53:100743. https:\/\/doi.org\/10.1016\/j.yfrne.2019.03.002","journal-title":"Front Neuroendocrinol"},{"key":"1491_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.schres.2020.04.031","volume":"222","author":"J Labad","year":"2020","unstructured":"Labad J, Montalvo I, Gonz\u00e1lez-Rodr\u00edguez A et al (2020) Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: a systematic review and meta-analysis. Schizophr Res 222:88\u201396. https:\/\/doi.org\/10.1016\/j.schres.2020.04.031","journal-title":"Schizophr Res"},{"key":"1491_CR34","doi-asserted-by":"crossref","unstructured":"Lewis DA, Lieberman JA (2000) Catching up on schizophrenia: Natural history and neurobiology. Neuron","DOI":"10.1016\/S0896-6273(00)00111-2"},{"key":"1491_CR35","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/acps.13530","volume":"147","author":"Z Li","year":"2023","unstructured":"Li Z, Wang Y, Wang Z et al (2023) Estradiol and raloxifene as adjunctive treatment for women with schizophrenia: a meta-analysis of randomized, double\u2010blind, placebo\u2010controlled trials. Acta Psychiatr Scand 147:360\u2013372. https:\/\/doi.org\/10.1111\/acps.13530","journal-title":"Acta Psychiatr Scand"},{"key":"1491_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41398-022-02027-4","volume":"12","author":"Z Lu","year":"2022","unstructured":"Lu Z, Sun Y, Zhang Y et al (2022) Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis. Transl Psychiatry 12:267. https:\/\/doi.org\/10.1038\/s41398-022-02027-4","journal-title":"Transl Psychiatry"},{"key":"1491_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11154-011-9184-2","volume":"13","author":"JA Markham","year":"2012","unstructured":"Markham JA (2012) Sex steroids and schizophrenia. Rev Endocr Metab Disord 13:187\u2013207. https:\/\/doi.org\/10.1007\/s11154-011-9184-2","journal-title":"Rev Endocr Metab Disord"},{"key":"1491_CR38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/JC.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of Hyperprolactinemia: an endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96:273\u2013288. https:\/\/doi.org\/10.1210\/JC.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"key":"1491_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2018.22","volume":"4","author":"S Meltzer-Brody","year":"2018","unstructured":"Meltzer-Brody S, Howard LM, Bergink V et al (2018) Postpartum psychiatric disorders. Nat Rev Dis Primers 4:1\u201318. https:\/\/doi.org\/10.1038\/nrdp.2018.22","journal-title":"Nat Rev Dis Primers"},{"key":"1491_CR40","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/0004867417744254","volume":"52","author":"I Montalvo","year":"2018","unstructured":"Montalvo I, Nadal R, Armario A et al (2018) Sex differences in the relationship between prolactin levels and impaired processing speed in early psychosis. Australian New Z J Psychiatry 52:585\u2013595. https:\/\/doi.org\/10.1177\/0004867417744254","journal-title":"Australian New Z J Psychiatry"},{"key":"1491_CR41","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.psyneuen.2013.02.007","volume":"38","author":"L Moore","year":"2013","unstructured":"Moore L, Kyaw M, Vercammen A et al (2013) Serum testosterone levels are related to cognitive function in men with schizophrenia. Psychoneuroendocrinology 38:1717\u20131728. https:\/\/doi.org\/10.1016\/j.psyneuen.2013.02.007","journal-title":"Psychoneuroendocrinology"},{"key":"1491_CR42","volume-title":"Mini international neuropsychiatric interview: Nederlandse Versie 5.0. 0","author":"I Overbeek","year":"1999","unstructured":"Overbeek I, Schruers K, Griez E (1999) Mini international neuropsychiatric interview: Nederlandse Versie 5.0. 0. DSM-IV [Dutch version] Maastricht, The Netherlands \u2026"},{"key":"1491_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40263-014-0157-3","volume":"28","author":"J Peuskens","year":"2014","unstructured":"Peuskens J, Pani L, Detraux J, De Hert M (2014) The effects of Novel and newly approved antipsychotics on serum prolactin levels: a Comprehensive Review. CNS Drugs 28:421\u2013453. https:\/\/doi.org\/10.1007\/s40263-014-0157-3","journal-title":"CNS Drugs"},{"key":"1491_CR70","unstructured":"a present address"},{"key":"1491_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/schbul\/sbz030","volume":"46","author":"TJ Reilly","year":"2020","unstructured":"Reilly TJ, Sagnay de la Bastida VC, Joyce DW et al (2020) Exacerbation of psychosis during the Perimenstrual phase of the Menstrual cycle: systematic review and Meta-analysis. Schizophr Bull 46:78\u201390. https:\/\/doi.org\/10.1093\/schbul\/sbz030","journal-title":"Schizophr Bull"},{"key":"1491_CR46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/schbul\/20.1.203","volume":"20","author":"A Riecher-Rossler","year":"1994","unstructured":"Riecher-Rossler A, Hafner H, Stumbaum M et al (1994) Can Estradiol modulate schizophrenic symptomatology? Schizophr Bull 20:203\u2013214. https:\/\/doi.org\/10.1093\/schbul\/20.1.203","journal-title":"Schizophr Bull"},{"key":"1491_CR45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S2215-0366(16)30379-0","volume":"4","author":"A Riecher-R\u00f6ssler","year":"2017","unstructured":"Riecher-R\u00f6ssler A (2017) Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses. Lancet Psychiatry 4:63\u201372. https:\/\/doi.org\/10.1016\/S2215-0366(16)30379-0","journal-title":"Lancet Psychiatry"},{"key":"1491_CR47","doi-asserted-by":"publisher","unstructured":"Roelfsema F, Pijl H, Keenan DM, Veldhuis JD (2012) Prolactin secretion in healthy adults is determined by gender, age and body mass index. PLoS ONE 7. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0031305","DOI":"10.1371\/JOURNAL.PONE.0031305"},{"key":"1491_CR48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/J.SCHRES.2015.04.039","volume":"166","author":"LH Rubin","year":"2015","unstructured":"Rubin LH, Carter CS, Drogos LL et al (2015) Effects of sex, menstrual cycle phase, and endogenous hormones on cognition in schizophrenia. Schizophr Res 166:269\u2013275. https:\/\/doi.org\/10.1016\/J.SCHRES.2015.04.039","journal-title":"Schizophr Res"},{"key":"1491_CR49","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1210\/JCEM.81.7.8675575","volume":"81","author":"BB Sherwin","year":"1996","unstructured":"Sherwin BB, Tulandi T (1996) Add-back estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 81:2545\u20132549. https:\/\/doi.org\/10.1210\/JCEM.81.7.8675575","journal-title":"J Clin Endocrinol Metab"},{"key":"1491_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1192\/bjp.181.1.49","volume":"181","author":"S Smith","year":"2002","unstructured":"Smith S, O\u2019Keane V, Murray R (2002a) Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 181:49\u201355. https:\/\/doi.org\/10.1192\/bjp.181.1.49","journal-title":"Br J Psychiatry"},{"key":"1491_CR51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00004714-200204000-00002","volume":"22","author":"S Smith","year":"2002","unstructured":"Smith S, Wheeler MJ, Murray R, O\u2019Keane V (2002b) The effects of Antipsychotic-Induced Hyperprolactinaemia on the hypothalamic-pituitary-gonadal Axis. J Clin Psychopharmacol 22:109\u2013114. https:\/\/doi.org\/10.1097\/00004714-200204000-00002","journal-title":"J Clin Psychopharmacol"},{"key":"1491_CR53","doi-asserted-by":"crossref","unstructured":"Sommer IE, Brand BA, Gangadin SS et al (2022) Women with schizophrenia-spectrum disorders after menopause; a vulnerable group for relapse. Schizophr Bull in","DOI":"10.1093\/schbul\/sbac139"},{"key":"1491_CR52","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/SCHBUL\/SBAC139","volume":"49","author":"IE Sommer","year":"2023","unstructured":"Sommer IE, Brand BA, Gangadin S et al (2023) Women with Schizophrenia-Spectrum disorders after Menopause: a Vulnerable Group for Relapse. Schizophr Bull 49:136\u2013143. https:\/\/doi.org\/10.1093\/SCHBUL\/SBAC139","journal-title":"Schizophr Bull"},{"key":"1491_CR54","doi-asserted-by":"crossref","unstructured":"Sun J, Walker AJ, Dean B et al (2016) Progesterone: The neglected hormone in schizophrenia? A focus on progesterone-dopamine interactions. Psychoneuroendocrinology","DOI":"10.1016\/j.psyneuen.2016.08.019"},{"key":"1491_CR55","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S2215-0366(21)00241-8","volume":"8","author":"H Taipale","year":"2021","unstructured":"Taipale H, Solmi M, L\u00e4hteenvuo M et al (2021) Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry 8:883\u2013891. https:\/\/doi.org\/10.1016\/S2215-0366(21)00241-8","journal-title":"Lancet Psychiatry"},{"key":"1491_CR56","doi-asserted-by":"crossref","unstructured":"Taylor AE, Keevil B, Huhtaniemi IT (2015) Mass spectrometry and immunoassay: how to measure steroid hormones today and tomorrow. Eur J Endocrinol","DOI":"10.1530\/EJE-15-0338"},{"key":"1491_CR57","doi-asserted-by":"publisher","unstructured":"Taylor DM, Barnes TRE, Young AH (2021) The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry. https:\/\/doi.org\/10.1002\/9781119870203","DOI":"10.1002\/9781119870203"},{"key":"1491_CR58","doi-asserted-by":"publisher","first-page":"e0187698","DOI":"10.1371\/journal.pone.0187698","volume":"12","author":"BJ Vandegrift","year":"2017","unstructured":"Vandegrift BJ, You C, Satta R et al (2017) Estradiol increases the sensitivity of ventral tegmental area dopamine neurons to dopamine and ethanol. PLoS ONE 12:e0187698. https:\/\/doi.org\/10.1371\/journal.pone.0187698","journal-title":"PLoS ONE"},{"key":"1491_CR59","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/J.CCA.2019.04.062","volume":"495","author":"SJE Verdonk","year":"2019","unstructured":"Verdonk SJE, Vesper HW, Martens F et al (2019) Estradiol reference intervals in women during the menstrual cycle, postmenopausal women and men using an LC-MS\/MS method. Clin Chim Acta 495:198\u2013204. https:\/\/doi.org\/10.1016\/J.CCA.2019.04.062","journal-title":"Clin Chim Acta"},{"key":"1491_CR60","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1212\/WNL.55.6.872","volume":"55","author":"J Verghese","year":"2000","unstructured":"Verghese J, Kuslansky G, Katz MJ et al (2000) Cognitive performance in surgically menopausal women on estrogen. Neurology 55:872\u2013874. https:\/\/doi.org\/10.1212\/WNL.55.6.872","journal-title":"Neurology"},{"key":"1491_CR75","doi-asserted-by":"crossref","unstructured":"Wechsler D (1997) Wechsler adult intelligence scale. Frontiers in Psychology.","DOI":"10.1037\/t49755-000"},{"key":"1491_CR61","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/mp.2015.11","volume":"20","author":"TW Weickert","year":"2015","unstructured":"Weickert TW, Weinberg D, Lenroot R et al (2015) Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry 20:685\u2013694. https:\/\/doi.org\/10.1038\/mp.2015.11","journal-title":"Mol Psychiatry"},{"key":"1491_CR62","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.biopsych.2016.03.2104","volume":"81","author":"JJ Weinstein","year":"2017","unstructured":"Weinstein JJ, Chohan MO, Slifstein M et al (2017) Pathway-specific dopamine abnormalities in Schizophrenia. Biol Psychiatry 81:31\u201342. https:\/\/doi.org\/10.1016\/j.biopsych.2016.03.2104","journal-title":"Biol Psychiatry"},{"key":"1491_CR63","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.4088\/JCP.15m10498","volume":"78","author":"M Weiser","year":"2017","unstructured":"Weiser M, Levi L, Burshtein S et al (2017) Raloxifene Plus antipsychotics Versus Placebo Plus antipsychotics in severely ill decompensated Postmenopausal Women with Schizophrenia or Schizoaffective Disorder. J Clin Psychiatry 78:e758\u2013e765. https:\/\/doi.org\/10.4088\/JCP.15m10498","journal-title":"J Clin Psychiatry"},{"key":"1491_CR64","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1842","author":"M Weiser","year":"2019","unstructured":"Weiser M, Levi L, Zamora D et al (2019) Effect of adjunctive estradiol on Schizophrenia among women of Childbearing Age: a Randomized Clinical Trial. JAMA Psychiatry. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1842","journal-title":"JAMA Psychiatry"},{"key":"1491_CR65","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/S11102-014-0576-7\/FIGURES\/4","volume":"18","author":"MB Whyte","year":"2015","unstructured":"Whyte MB, Pramodh S, Srikugan L et al (2015) Importance of cannulated prolactin test in the definition of hyperprolactinaemia. Pituitary 18:319\u2013325. https:\/\/doi.org\/10.1007\/S11102-014-0576-7\/FIGURES\/4","journal-title":"Pituitary"},{"key":"1491_CR66","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.3760\/CMA.J.ISSN.0376-2491.2016.27.009","volume":"96","author":"X Yuan","year":"2016","unstructured":"Yuan X, Zhu Q, Liang H et al (2016) [Correlations between hormone levels and psychiatric symptoms as well as cognitive function in drug-free first-episode schizophrenics]. Zhonghua Yi Xue Za Zhi 96:2155\u20132160. https:\/\/doi.org\/10.3760\/CMA.J.ISSN.0376-2491.2016.27.009","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"1491_CR67","doi-asserted-by":"publisher","unstructured":"Zhang L, Qi H, Xie YY et al (2021) Efficacy and safety of Adjunctive Aripiprazole, Metformin, and Paeoniae-Glycyrrhiza Decoction for Antipsychotic-Induced Hyperprolactinemia: A Network Meta-Analysis of Randomized controlled trials. Front Psychiatry 12. https:\/\/doi.org\/10.3389\/FPSYT.2021.728204","DOI":"10.3389\/FPSYT.2021.728204"}],"container-title":["Archives of Women's Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-024-01491-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00737-024-01491-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-024-01491-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T04:53:12Z","timestamp":1732078392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00737-024-01491-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1491"],"URL":"https:\/\/doi.org\/10.1007\/s00737-024-01491-9","relation":{},"ISSN":["1434-1816","1435-1102"],"issn-type":[{"value":"1434-1816","type":"print"},{"value":"1435-1102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"18 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For the European clinical trial, ethical permission was obtained from the Medical Ethical committee of the University Medical Centre of Utrecht (16\u2013103) in the Netherlands. For the Australian study, ethical permission was obtained from the University of New South Wales (07\/121 and 09\/187) and the South Eastern Sydney and Illawarra Area Health Service (07-259) and the Queen Elizabeth Hospital Ethics and Human Research Committee, Adelaide (2010188) for Australian subjects. Studies were carried out in accordance with the Declaration of Helsinki of 1975, as revised in 2008. All participants gave written informed consent prior to inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"CSW is a recipient of a National Health and Medical Research Council (Australia) Investigators Grant Leadership 3 (RG210864). BAB, JNB, EJMW, IEC, and TWW declare they have no financial interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Non-financial interests"}}]}}